
Aiwu Ruth He, MD, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal and gastric cancers and which patients are most likely to benefit from the anti–PD-1 agents.

Your AI-Trained Oncology Knowledge Connection!


Published: January 8th 2020 | Updated: